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Frankfurt am Main, GermanyAccording to the WHO more than 170 million people are infected
with the hepatitis C virus (HCV), causing a slowly ﬁbrosing hep-
atitis that subsequently can lead to cirrhosis and its sequelae.
Chronic hepatitis C is one of the most common causes of liver
disease and cancer world-wide.
The development of direct-acting antivirals (DAAs) has revo-
lutionized HCV treatment by offering genuine prospects for the
ﬁrst comprehensive cure of a chronic viral infection in man [1].
This unprecedented success is due to important scientiﬁc,
clinical, and regulatory developments [1] and has resulted in
novel treatment approaches, rapidly changing the management
of HCV-infected patients [2].
25 years following the discovery of the virus, the Journal takes
the opportunity to highlight milestones in basic science and clin-
ical developments and review the remaining challenges in the
prevention and treatment of HCV infection. The discovery of
the virus, using an expression cloning approach, the characteriza-
tion of its genome and life cycle, and the development of novel
model systems have provided the base for the development of
DAAs and complementary therapeutic approaches. Dr. Cosset
and Dr. Dubuisson are reviewing the latest discoveries in the
molecular virology of HCV infection. HCV infection has been
proven to be a unique model to understand the mechanism of
viral evasion and how the virus enables persistent infection. Dr.
Thimme and Dr. Heim present an overview on previous and
new ﬁndings in antiviral innate and adaptive immune responses
and how these are interrelated. Dr. Lauer, Dr. Baumert and
colleagues present how this knowledge can be applied to develop
a vaccine and which challenges remain to accomplish this
important task. A key challenge for vaccine development and
for understanding the pathogenesis of HCV-induced liver disease
is the lack of suitable animal models. Dr. Meuleman and col-
leagues highlight what has been accomplished so far and discuss
the next challenges for the development of disease biology
models.Journal of Hepatology 20
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Open access under CC BY-NC-ND license.The clinical investigation of the disease has led to a better
understanding of its natural course as well as its association with
comorbidities. The data on the natural course of hepatitis C virus
infection (including aspects of spontaneous or treatment-induced
resolution) are presented in this Supplement by Dr. Dusheiko and
Dr. Westbrook. HCV infection is one of the leading causes of
hepatocellular carcinoma worldwide. Emerging data suggest that
viral cure reduces but does not eliminate the risk for HCC
development. Dr. Hoshida, Dr. Chung and colleagues review the
mechanisms of HCC pathogenesis and perspectives on how to
prevent this lethal disease. Hepatitis C virus infection and a
number of comorbidities are considered to be interrelated.
Dr. Negro provides a comprehensive overview on facts and
ﬁctions in this clinically important ﬁeld.
The development of interferon-free all oral combination ther-
apies for hepatitis C represents one of the fastest revolutions in
medicine ever [1,2]. Generally, two distinct strategies are pur-
sued: one with and others without a nucleosidic polymerase
inhibitor. The nucleoside polymerase inhibitor sofosbuvir was
successfully combined in a step-up process with NS3/4A protease
inhibitors, NS5A-inhibitors, and non-nucleosidic polymerase
inhibitors plus or minus ribavirin. A ﬁxed drug combination,
consisting of sofosbuvir and the NS5A-inhibitor ledipasvir, has
completed phase 3 trials in treatment-naive and experienced
patients and achieved sustained virologic response rates above
95%. All relevant clinical trials are summarized by Dr. Jacobson
and Dr. Kumar. The second strategy combines all drug classes
but nucleosidic polymerase inhibitors – NS3/4A protease inhibi-
tors, NS5A-inhibitors, non-nucleosidic polymerase inhibitors
and ribavirin – in a step-down process. The combination of riton-
avir-boosted ABT-450, with ombitasvir, dasabuvir and ribavirin
also achieved sustained virologic response rates above 95% both
in treatment-naive as in treatment-experienced patients with
chronic hepatitis C. This and other studies without a nucleosidic
polymerase inhibitors are summarized in this Supplement by
Drs. Welzel, Dultz, and Zeuzem.
The most challenging treatment approach is resembled by
previously difﬁcult to cure patients (decompensated cirrhosis,
patients under immunosuppressive therapy, co-infected patients,
etc.). The management of HCV/HIV coinfected patients is
presented by Dr. Sulkowski, while Dr. Forns and colleagues sum-
marize the current knowledge on how to manage and treat14 vol. 61 j S1–S2
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patients with decompensated cirrhosis as well as patients pre-
and post-transplantation. A key challenge is access to treatment,
Dr. Ford, Dr. Wiktor and colleagues review how to promote access
to treatment through evidence based recommendations. Basis for
this approach is the detailed understanding of the global
epidemiology and genotype distribution of the hepatitis C virus,
which in this Supplement is comprehensively summarized by
Dr. Razavi and colleagues.
The Editors of this Supplement are convinced that the most
important aspects in the ﬁeld of hepatitis C are covered by leading
experts in the ﬁeld and that themanuscripts provide a comprehensive
overview on the current knowledge and are state-of-the-art.S2 Journal of Hepatology 20Conﬂict of interest
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